Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2024-05-21 Investor Presentation
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
投资者关系活动记录表
Investor Presentation Classification · 90% confidence The document is an investor relations activity record from Shanxi Jinbo Biopharmaceutical Co., Ltd. It details a 2024 investor online collective reception day and annual report performance briefing held on May 20, 2024. The content includes Q&A about company strategy, shareholding plans, and product applications. It is not the annual report itself but a record of an investor relations event discussing the annual report and company performance. The document length is short (1447 characters) and it serves as a summary of an investor meeting rather than a full financial report or earnings release. Therefore, it fits best under Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, rather than a formal earnings release or annual report.
2024-05-21 Chinese
投资者关系活动记录表
Regulatory Filings Classification · 95% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record." It details a specific investor relations event held on May 14, 2024, including participants, discussion topics about product strategy, sales, marketing, and cooperation with other companies. The content is a record of an investor relations meeting or research session rather than a formal financial report or earnings release. It is not an earnings release (ER) because it does not present financial results or highlights. It is not an investor presentation (IP) because it is a record of an event, not a presentation document. It is not a regulatory filing or announcement of a report. The document fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement or investor relations activity record that does not fit other specific categories.
2024-05-15 Chinese
关于参加山西辖区上市公司2024年投资者网上集体接待日暨年报业绩说明会的预告公告
Investor Presentation Classification · 90% confidence The document is a notice about the company's participation in an investor online collective reception day and annual report performance explanation meeting. It includes details about the meeting type, time, location, participants, and how investors can join. It does not contain the actual annual report or financial data but rather announces an event related to the annual report. The document length is short (781 characters), and it serves as an announcement rather than the report itself. Therefore, it fits the category of Investor Presentation (IP) since it is about a presentation event focused on financial results and investor interaction.
2024-05-13 Chinese
关于更换持续督导保荐代表人的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of continuous supervision sponsor representatives for the company. It details personnel changes in the sponsor representatives assigned by the securities firm and includes a brief biography of the new representative. There is no financial data, no report attached or referenced as being published, and no mention of financial results or regulatory filings beyond this personnel update. This fits the category of Board/Management Information (MANG), as it concerns changes in company representatives related to governance and oversight roles.
2024-05-13 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "山西锦波生物医药股份有限公司 2024 年第一季度报告" which translates to "Shanxi Jinbo Biopharmaceutical Co., Ltd. 2024 First Quarter Report." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the period January to March 2024. The document explicitly states it is a quarterly report (第一季度报告) and includes comprehensive financial statements and management commentary on financial results. It is unaudited as noted. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-21 Chinese
第三届监事会第二十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the Supervisory Board of Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of the proposal regarding the company's 2024 first quarter report. However, the actual quarterly report is not included in this document; instead, it states that the report has been published separately on the Beijing Stock Exchange information disclosure platform with a specific announcement number. The document is short (864 characters) and serves as an announcement of the meeting resolution and the approval of the quarterly report, not the report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement rather than an Interim/Quarterly Report (IR).
2024-04-21 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.